ETON Stock Overview
A specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ETON from our risk checks.
Eton Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.67 |
| 52 Week High | US$5.81 |
| 52 Week Low | US$3.03 |
| Beta | 1.3 |
| 11 Month Change | 25.54% |
| 3 Month Change | 28.65% |
| 1 Year Change | -11.39% |
| 33 Year Change | -4.89% |
| 5 Year Change | -32.02% |
| Change since IPO | -25.28% |
Recent News & Updates
Recent updates
After Leaping 26% Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Are Not Flying Under The Radar
Sep 10
Subdued Growth No Barrier To Eton Pharmaceuticals, Inc. (NASDAQ:ETON) With Shares Advancing 40%
Jan 09The Consensus EPS Estimates For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Just Fell A Lot
Dec 13Eton Pharmaceuticals' (NASDAQ:ETON) Earnings May Just Be The Starting Point
Nov 16Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Despite Losing Money
Sep 30Not Many Are Piling Into Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Stock Yet As It Plummets 26%
Jul 25Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?
Jun 29Is Eton Pharmaceuticals (NASDAQ:ETON) Using Debt In A Risky Way?
Dec 22Eton Pharmaceuticals acquires FDA-approved rare disease product betaine anhydrous
Sep 13Eton Pharmaceuticals: An Evolving 'Sum Of The Parts' Story
Aug 14Eton Pharma jumps 20% on FDA approval of seizure therapy
Jul 18Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging Higher
Apr 15Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely
Oct 14Another Look At Eton Pharmaceuticals
Sep 03What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their Estimates
Aug 18Eton Pharma wins FDA approval for Rezipres
Jun 15FDA declines to approve Eton Pharmaceuticals' methanol poisoning treatment
May 28Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Is About To Turn The Corner
May 15Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?
Apr 05Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful?
Mar 01Eton Pharma buys Canadian rights for Alkindi Sprinkle
Jan 14Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Shift From Loss To Profit
Jan 07
Shareholder Returns
| ETON | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 1.5% | -2.7% | -3.4% |
| 1Y | -11.4% | 15.8% | 19.6% |
Return vs Industry: ETON underperformed the US Pharmaceuticals industry which returned 15.8% over the past year.
Return vs Market: ETON underperformed the US Market which returned 19.6% over the past year.
Price Volatility
| ETON volatility | |
|---|---|
| ETON Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 10.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ETON's share price has been volatile over the past 3 months.
Volatility Over Time: ETON's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 30 | Sean Brynjelsen | www.etonpharma.com |
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis.
Eton Pharmaceuticals, Inc. Fundamentals Summary
| ETON fundamental statistics | |
|---|---|
| Market cap | US$120.66m |
| Earnings (TTM) | -US$6.69m |
| Revenue (TTM) | US$31.38m |
3.8x
P/S Ratio-18.0x
P/E RatioIs ETON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ETON income statement (TTM) | |
|---|---|
| Revenue | US$31.38m |
| Cost of Revenue | US$12.72m |
| Gross Profit | US$18.67m |
| Other Expenses | US$25.35m |
| Earnings | -US$6.69m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.26 |
| Gross Margin | 59.48% |
| Net Profit Margin | -21.31% |
| Debt/Equity Ratio | 34.6% |
How did ETON perform over the long term?
See historical performance and comparison